German protein analysis company Caprotec Bioanalytics this week announced the creation of a US subsidiary, Caprotec, and appointed Christian Jurinke as president of the unit.
Jurinke has a 12-year history of developing and commercializing products for life-science ventures. He joined Caprotec in 2008 to head the company's key product commercialization efforts and to help manage the firm's distribution channels. Prior to joining Caprotec, he was at Sequenom where he held a number of senior management positions.
The US subsidiary is based in Burlington, Mass., and is partnering with consulting firm Genovative Solutions for the marketing and sales of Caprotec products. Jeff Protentis, founder of Genovative, will act as Caprotec's lead US agent.
Kinaxo Biotechnologies this week said that Jürgen Schumacher has been elected to the company's advisory board.
His election was part of the German chemical proteomics firm's announcement that it had completed a financing round to develop novel biomarkers that allow the stratification of cancer patients receiving targeted therapies.
Schumacher is a co-founder of Qiagen and principal founder of NewLab Bioquality, which was sold to Charles River Laboratories last year. He also serves on the board of several biotechnology firms.
Kinaxo did not disclose how much money it raised in the financing round, but its CEO and co-founder told ProteoMonitor's sister publication, GenomeWeb Daily News that the company will invest €3 million to €4 million ($4.5 million to $5.9 million) in biomarker development during the next two years.
Two new investors participated in the round: investment holding company Leifina and Conmit Invest. Existing shareholders Axel Ullrich, Hellmut Kirchner, and Manfred Gerber and institutional investors Mountain Partners, BioM, High-Tech Gründerfonds, the Max-Planck Society, and the KfW ERP Start-Fonds were also participants.